

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP PRODUCTS LIABILITY LITIGATION	MDL No. 2741 Case No. 16-md-02741-VC
This document relates to: ALL ACTIONS	<b>PRETRIAL ORDER NO. 88: DEPOSITION DESIGNATIONS FOR DR. MATTHEW ROSS</b>  Re: Dkt. No. 2808

As made clear in the Court's ruling on Monsanto's Motion in Limine No. 1, the parties are precluded from presenting evidence of IARC's process or analysis during Phase 1. The only exceptions to this ruling are that the plaintiff's experts may testify to the fact of the IARC classification, and they may reference IARC's independent meta-analysis. The portions of the deposition testimony designated by both sides are, aside from the background information about Dr. Ross's training and experience, almost exclusively related to IARC's process and analysis. Therefore, his deposition testimony is not admissible during Phase 1. Having reviewed the designations and counter-designations, the Court is tentatively of the view that all of them, or virtually all of them, would be admissible in Phase 2, but the Court will await a new submission from the parties about any deposition testimony they wish to designate from Dr. Ross in Phase 1.

**IT IS SO ORDERED.**

Date: February 25, 2019

  
\_\_\_\_\_  
Honorable Vince Chhabria  
United States District Court